TMO - TMO サ―モ・フィッシャ―・サイエンティフィック （）

NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Major players in the single-use assemblies market are Avantor Inc., Corning Incorporated, Danaher Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Saint-Gobain, Parker Hannifin Corporation, Repligen Corporation, Newage…

NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Major players in the clinical chemistry market are Abbott Laboratories, F. Hoffmann-La Roche Ltd., ELITech Group, Beckman Coulter Inc., Thermo Fisher Scientific Inc., Siemens AG, Ortho Clinical Diagnostics, Diatron Mi Apac Private Limited, Nova…

The marketing authorization makes Thermo Fisher’s SeCore CDx HLA Sequencing System the first and so far only commercially available HLA typing companion diagnostic.

https://www.investing.com/news/pro/rbc-capital-starts-thermo-fisher-scientific-at-outperform-432SI-2958574

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a new 2030 greenhouse gas emissions reduction target to reduce its Scope 1 and 2 emissions from operations by more than 50% from a 2018 baseline.1 The company is on track to achieve its previous 2030 goal of a 30% reduction, ahead of schedule. The company’s new 50% reduction target fulfills its commitment to the Business Ambition to 1.5˚C campaign and aligns its clima

Related Stocks: DEO , GOOG , TMO , MSFT , CHTR ,

https://www.investing.com/news/pro/thermo-fisher-scientific-pt-lowered-to-665-at-baird-432SI-2927901

Thermo Fisher Scientific (NYSE: TMO), the supplier of scientific instrumentation, announced on Monday that it will acquire The Binding Site Group, a specialty diagnostics company headquartered in Birmingham, UK for $2.6 billion. Thermo Fisher will acquire Binding Site from a shareholder group led by private equity firm Nordic Capital. Binding Site''s business has been growing by around 10% every year and is on track to deliver revenues in excess of $220 million in 2022. Marc N. Casper, Chairman, President, and CEO of Thermo Fisher commented, "This transaction perfectly aligns with our Mission and is an exciting addition to our existing specialty diagnostic offerings.

Ford (F), Emerson Electric (EMR), Thermo Fisher (TMO), XPeng (XPEV), Li Auto (LI), Alibaba (BABA), JD.com (JD) and Baidu (BIDU) are among the stocks to watch on Monday.

Thermo Fisher Scientific Inc said on Monday it would buy Binding Site Group from European private equity firm Nordic Capital in an all-cash transaction valued at 2.25 billion pounds ($2.6 billion), boosting its specialty diagnostics business. Birmingham, U.K.-based Binding Site’s test helps detect and monitor multiple myeloma, a cancer in a type of white blood […]

Thermo Fisher Scientific signed an eight-year virtual power purchasing agreement with Enel North America to deliver a 90-megawatt (MW) portion of the Seven Cowboy wind project in western Oklahoma The post Thermo Fisher Scientific America Signs 8 Year PPA for Half of Its Electricity Needs appeared first on Environment + Energy Leader .

The US FDA has granted approval to Thermo Fisher Scientific''s (TMO) Oncomine Dx Target test to help determine which cancer patients may benefit from Eli Lilly’s (LLY)…

Source: Ruslan Ivantsov / Shutterstock.com Wall Street has officially entered a bear market. Macroeconomic headwinds continue to build, including rampant inflation, slowing economic growth and continued geopolitical turmoil. We now have further uncertainty surrounding the stock market following the most recent interest rate hike. As we enter a bear market, investors are searching for alternative investment paths for diversification. Growth names that were the darlings on Wall Street during the pandemic have not been immune to these challenges so far in the year. Even large-capitalization (cap) shares have come under pressure since January. Year-to-date (YTD), the S&P 500 index has so far dropped over 22.9% year-to-date (YTD), while the tech-heavy Nasdaq 100 has declined more than 30.7% during the same period. In the past century, we have had over 25 bear markets on the Street. Most have lasted an average of less than one year. While it may be tempting to sell stocks in the portfolio to minimize losses, panic selling in a bear market often leads to loss of potential profits and even investment capital.

WILMINGTON, DE / ACCESSWIRE / September 26, 2022 / Transparency Market Research Inc. - Rising use of automation in various healthcare and biotech research processes is creating attractive opportunities in the global molecular diagnostics market . This trend is further bolstered by the rising need for incorporating automation for facilitating various processes, including extraction of DNA, amplification, and analyzing and recording healthcare data. These automated systems offer various benefits, such as higher efficiency, precise output, and reduced time required for gaining results. Based on a recent research report, the global molecular diagnostics market is estimated to rise at a CAGR of 11.1% over the forecast period of 2021 to 2028. Get Exclusive PDF Sample Copy of Molecular Diagnostics Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1783 Growing adoption of molecular diagnostic devices in various diagnostic laboratories, biotech and pharma companies, hospitals, and research and academic institutes is creating growth opportunities for players in the global molecular diagnostics market in developed economies.

Thermo Fisher Scientific Inc with ticker code (TMO) now have 22 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 715 and 525 with a mean TP of 659.91. Now with the previous closing price of 520.29 this would indicate that there is a potential upside of 26.8%. There is a 50 day moving average of 567.14 while the 200 day moving average is 570.34. The market capitalisation for the company is $204,040m. Company Website: https://www.thermofisher.com [stock_market_widget type="chart" template="basic" color="green" assets="TMO" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $258,794m based on the market concensus. Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company''s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.